Use of Infliximab in the Treatment of Macrophage Activation Syndrome Complicating Kawasaki Disease
| Autor: | Marco Antonio Yamazaki-Nakashimada, Luis Martín Garrido-García, Edwin Pardo-Díaz, Marco A Ruiz-Ontiveros, Andrea Iglesias-Amaya, Selma Scheffler-Mendoza, Leonardo Rivera-Rodríguez, Sarbelio Moreno-Espinosa |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.drug_class Mucocutaneous Lymph Node Syndrome Monoclonal antibody Young Adult 03 medical and health sciences 0302 clinical medicine Adrenal Cortex Hormones immune system diseases hemic and lymphatic diseases DiGeorge syndrome medicine Humans business.industry Macrophage Activation Syndrome Immunoglobulins Intravenous Gamma globulin Hematology medicine.disease Infliximab Oncology Child Preschool 030220 oncology & carcinogenesis Macrophage activation syndrome Pediatrics Perinatology and Child Health Immunology Cyclosporine Female Tumor necrosis factor alpha Kawasaki disease Dermatologic Agents business 030215 immunology Systemic vasculitis medicine.drug |
| Zdroj: | Journal of Pediatric Hematology/Oncology. 43:e448-e451 |
| ISSN: | 1077-4114 |
| DOI: | 10.1097/mph.0000000000001756 |
| Popis: | Kawasaki disease (KD) is an acute systemic vasculitis of unknown etiology. KD can be complicated with macrophage activation syndrome. The optimal treatment for this KD complication has not been established, and a variety of treatments have been used. Infliximab, a chimeric monoclonal antibody that binds tumor necrosis factor, has proved to be efficacious in IV gammaglobulin resistant KD. We present 2 cases of KD complicated with macrophage activation syndrome, including 1 patient with DiGeorge syndrome successfully treated with a combined treatment of IV gammaglobulin, corticosteroids, cyclosporine, and infliximab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|